Provides a definitive, state-of-the-art review of relevant tumor biology and its importance in the broader context of cancer biology Over the past two decades, a better understanding of the biology of lymphoid malignancies has led to the development of many classes of new, highly active drugs that present opportunities to impact the clinical outcome of many patients. Precision Cancer Therapies, Volume Two: Immunologic Approaches for the Treatment of Lymphoid Malignancies, focuses on agents that mediate cell killing in lymphoma through a variety of immunologic mechanisms. This authoritative…mehr
Provides a definitive, state-of-the-art review of relevant tumor biology and its importance in the broader context of cancer biology Over the past two decades, a better understanding of the biology of lymphoid malignancies has led to the development of many classes of new, highly active drugs that present opportunities to impact the clinical outcome of many patients. Precision Cancer Therapies, Volume Two: Immunologic Approaches for the Treatment of Lymphoid Malignancies, focuses on agents that mediate cell killing in lymphoma through a variety of immunologic mechanisms. This authoritative reference covers targeting of cell surface receptors, antibody-drug conjugates (ADC), targeting immune checkpoint, targeting macrophages, EBV-directed immunotherapies, tumor-associated antigens (TAA), and chimeric antigen receptor T-cells (CAR-T). In-depth chapters on specific therapeutics or therapeutic classes include a basic explanation of the underlying pathway and target, the pharmacology of the drug/class, relevant preclinical and clinical data, and discussion of clinical management and potential predictive biomarkers of response. Information on monotherapy and combination therapy, summary tables of trials, discussion of toxicity and efficacy, and boxed sections highlighting major points are integrated throughout the text. Authored and edited by the foremost authorities in the field, Precision Cancer Therapies, Volume Two: Immunologic Approaches for the Treatment of Lymphoid Malignancies is an indispensable resource for medical, scientific, and allied medical professionals. The Precision Cancer Therapies series helps professionals understand and translate fundamental basic science into information that can be directly applied to patients to advance care. Each volume of the series integrates the relevant biological concepts and principles necessary for translating this science to practitioners.
OWEN A. O'CONNOR, MD, PhD, American Cancer Society Research Professor; Professor of Medicine, University of Virginia Cancer Center, Charlottesville, VA, USA. STEPHEN M. ANSELL, MD, PhD, Consultant, Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA. JOHN G. GRIBBEN, MD, DSc, Hamilton-Fairley Chair of Medical Oncology, Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, UK.
Inhaltsangabe
List of Contributors xix Volume Foreword xxiv Volume Preface xxvi Series Preface xxviii Section I Historical Perspective 1 1 The Distinguished History of Immunotherapy Development in Cancer 3 Stephen M. Ansell Section II Targeting Cell Surface Receptors 9 2 Development of Monoclonal Antibodies for the Treatment of Lymphoma: Setting the Stage 11 George J. Weiner 3 Pharmacology to Practice: The Similarities and Differences of Drugs Targeting CD20 22 Jennifer K. Lue and Bruce D. Cheson 4 Pharmacology to Practice: Targeting CD19 and 22 40 Nilanjan Ghosh and Sonali M. Smith 5 Targeting Other Promising Cell Surface Receptors: ROR1, CD38, CD25, and CCR4 52 Michael Wang Section III Antibody Drug Conjugates (ADC) 73 6 Principles of Antibody Drug Development 75 Eric L. Sievers 7 Targeting CD30 in Lymphoid Neoplasms 87 Barbara Pro 8 Targeting CD79b in B-cell Malignancies 100 Colette Owens and Gilles Salles 9 Radioimmunotherapy: Is There Any Future Role? 108 Alessandro Broccoli and Pier Luigi Zinzani Section IV Targeting Immune Checkpoint 123 10 The Biology of Immune Checkpoint Blockade 125 Timothy N. Bullock 11 Mechanism of Action and Pharmacologic Features of Drugs Targeting PD-1/PDL-1 and CTLA-4 139 Marc-Anthony Rodriguez, Ryan Bucktrout, Andrea Orlando, Inna Serganova, and Roberta Zappasodi 12 Other Immune Checkpoint Targets of Interest 156 Clifford M. Csizmar and Stephen M. Ansell 13 Clinical Experiences with Immune Checkpoint Inhibitors in Lymphomas 190 John M. Timmerman Section V Targeting Macrophages and SIRP-alpha - Disrupting the "Do Not Eat Me" 209 14 The Role of CD47 in Lymphoma Biology and Strategies for Therapeutic Targeting 211 Mithunah Krishnamoorthy, Robert A. Uger, and Mark Wong 15 Single Agent and Rational Combination Experiences with Anti-CD47 Targeted Drugs 225 Nadia Khan, Swathi Namburi, and Krish Patel Section VI EBV Directed Immunotherapies 233 16 Understanding the Role of EBV Infection in Lymphomagenesis 235 Hiroshi Kimura and Takayuki Murata 17 Immunologic Therapies in Development for EBV Driven Lymphoid Malignancies 246 Jason Yongsheng CHAN, Seok Jin Kim, Soon Thye LIM, Choon Kiat ONG, and Won Seog Kim Section VII Exploiting Tumor Associated Antigens with Autologous T-Cells 257 18 The Scientific Rationale for Targeting Tumor-Associated Antigens 259 Jean-Sébastien Delisle and Marie-France Aubin 19 Clinical Experiences with TAA-T in Lymphoid Malignancies 276 Keri Toner, Hannah Kinoshita, and Catherine M. Bollard Section VIII Chimeric Antigen Receptor T-Cells (CAR-T) 289 20 The Science of CAR-T Cell Technology 291 Richard C. Godby, Allison M. Bock, Saad S. Kenderian, and Yi Lin 21 The Spectrum of CAR T Assets in Development: Similarities and Differences 304 J. Erika Haydu and Jeremy S. Abramson 22 Clinical Experience with CAR-T Cells for Treatment of B-cell Lymphomas 318 Stephen J. Schuster and John G. Gribben 23 "Off the Shelf" CAR-T/NK Cells 341 Nancy D. Marin, Alice Zhou, Miriam T. Jacobs, and Todd A. Fehniger 24 Programming Myeloid Cells with Chimeric Antigen Receptor Myeloid-Based Therapies 360 Miriam Barnett, Michele Gerber, Siddartha Mukherjee, and Daniel Getts Section IX Miscellaneous Topics in Immunotherapy 373 25 Mechanistic Basis and Role of Immunomodulatory Drugs 375 John G. Gribben 26 Analytical Tools to Quantitate Immune Mediated Effects: What Should We Measure and How? 384 Kevin D. Pavelko and Jose C. Villasboas 27 The Role of the Microbiome in Immune Response 397 Máire A. Conrad, Kathleen E. Sullivan, and Judith Kelsen 28 Epigenetic Drugs as Modulators of Tumor Immunogenicity and Host Immune Response 406 Enrica Marchi, Ipsita Pal, John Sanil Manvalan, Kallesh Danappa Jayappa, and Owen A. O'Connor 29 Tailoring Specific Radiographic Response Criteria for Immunologic Therapies in Lymphoma 429 Bruce D. Cheson Conclusions 433 Must Reads 433 References 433 Index 436
List of Contributors xix Volume Foreword xxiv Volume Preface xxvi Series Preface xxviii Section I Historical Perspective 1 1 The Distinguished History of Immunotherapy Development in Cancer 3 Stephen M. Ansell Section II Targeting Cell Surface Receptors 9 2 Development of Monoclonal Antibodies for the Treatment of Lymphoma: Setting the Stage 11 George J. Weiner 3 Pharmacology to Practice: The Similarities and Differences of Drugs Targeting CD20 22 Jennifer K. Lue and Bruce D. Cheson 4 Pharmacology to Practice: Targeting CD19 and 22 40 Nilanjan Ghosh and Sonali M. Smith 5 Targeting Other Promising Cell Surface Receptors: ROR1, CD38, CD25, and CCR4 52 Michael Wang Section III Antibody Drug Conjugates (ADC) 73 6 Principles of Antibody Drug Development 75 Eric L. Sievers 7 Targeting CD30 in Lymphoid Neoplasms 87 Barbara Pro 8 Targeting CD79b in B-cell Malignancies 100 Colette Owens and Gilles Salles 9 Radioimmunotherapy: Is There Any Future Role? 108 Alessandro Broccoli and Pier Luigi Zinzani Section IV Targeting Immune Checkpoint 123 10 The Biology of Immune Checkpoint Blockade 125 Timothy N. Bullock 11 Mechanism of Action and Pharmacologic Features of Drugs Targeting PD-1/PDL-1 and CTLA-4 139 Marc-Anthony Rodriguez, Ryan Bucktrout, Andrea Orlando, Inna Serganova, and Roberta Zappasodi 12 Other Immune Checkpoint Targets of Interest 156 Clifford M. Csizmar and Stephen M. Ansell 13 Clinical Experiences with Immune Checkpoint Inhibitors in Lymphomas 190 John M. Timmerman Section V Targeting Macrophages and SIRP-alpha - Disrupting the "Do Not Eat Me" 209 14 The Role of CD47 in Lymphoma Biology and Strategies for Therapeutic Targeting 211 Mithunah Krishnamoorthy, Robert A. Uger, and Mark Wong 15 Single Agent and Rational Combination Experiences with Anti-CD47 Targeted Drugs 225 Nadia Khan, Swathi Namburi, and Krish Patel Section VI EBV Directed Immunotherapies 233 16 Understanding the Role of EBV Infection in Lymphomagenesis 235 Hiroshi Kimura and Takayuki Murata 17 Immunologic Therapies in Development for EBV Driven Lymphoid Malignancies 246 Jason Yongsheng CHAN, Seok Jin Kim, Soon Thye LIM, Choon Kiat ONG, and Won Seog Kim Section VII Exploiting Tumor Associated Antigens with Autologous T-Cells 257 18 The Scientific Rationale for Targeting Tumor-Associated Antigens 259 Jean-Sébastien Delisle and Marie-France Aubin 19 Clinical Experiences with TAA-T in Lymphoid Malignancies 276 Keri Toner, Hannah Kinoshita, and Catherine M. Bollard Section VIII Chimeric Antigen Receptor T-Cells (CAR-T) 289 20 The Science of CAR-T Cell Technology 291 Richard C. Godby, Allison M. Bock, Saad S. Kenderian, and Yi Lin 21 The Spectrum of CAR T Assets in Development: Similarities and Differences 304 J. Erika Haydu and Jeremy S. Abramson 22 Clinical Experience with CAR-T Cells for Treatment of B-cell Lymphomas 318 Stephen J. Schuster and John G. Gribben 23 "Off the Shelf" CAR-T/NK Cells 341 Nancy D. Marin, Alice Zhou, Miriam T. Jacobs, and Todd A. Fehniger 24 Programming Myeloid Cells with Chimeric Antigen Receptor Myeloid-Based Therapies 360 Miriam Barnett, Michele Gerber, Siddartha Mukherjee, and Daniel Getts Section IX Miscellaneous Topics in Immunotherapy 373 25 Mechanistic Basis and Role of Immunomodulatory Drugs 375 John G. Gribben 26 Analytical Tools to Quantitate Immune Mediated Effects: What Should We Measure and How? 384 Kevin D. Pavelko and Jose C. Villasboas 27 The Role of the Microbiome in Immune Response 397 Máire A. Conrad, Kathleen E. Sullivan, and Judith Kelsen 28 Epigenetic Drugs as Modulators of Tumor Immunogenicity and Host Immune Response 406 Enrica Marchi, Ipsita Pal, John Sanil Manvalan, Kallesh Danappa Jayappa, and Owen A. O'Connor 29 Tailoring Specific Radiographic Response Criteria for Immunologic Therapies in Lymphoma 429 Bruce D. Cheson Conclusions 433 Must Reads 433 References 433 Index 436
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Shop der buecher.de GmbH & Co. KG Bürgermeister-Wegele-Str. 12, 86167 Augsburg Amtsgericht Augsburg HRA 13309
